Purified oral cannabidiol for pain management in severe recessive dystrophic epidermolysis bullosa
Indian J Dermatol Venereol Leprol
.
2022 May-Jun;88(4):551-552.
doi: 10.25259/IJDVL_71_2021.
Authors
Tobias Welponer
1
,
Anja Diem
1
,
Gerhard Nahler
2
,
Martin Laimer
1
Affiliations
1
Department of Dermatology and Allergology and EB House, University Hospital of the Paracelsus Medical University, Salzburg, Austria.
2
Clinical Investigation Support GmbH, Vienna, Austria.
PMID:
35593277
DOI:
10.25259/IJDVL_71_2021
No abstract available
Publication types
Letter
MeSH terms
Cannabidiol*
Epidermolysis Bullosa Dystrophica* / complications
Epidermolysis Bullosa Dystrophica* / diagnosis
Epidermolysis Bullosa Dystrophica* / drug therapy
Epidermolysis Bullosa*
Humans
Pain Management
Skin
Substances
Cannabidiol